Receptor (biochemistry)

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Retrieved on: 
Monday, January 22, 2024

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

Key Points: 
  • USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
    COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.
  • The milestone relates to the validation of GMP manufacturing of finished product.
  • The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023.
  • Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Retrieved on: 
Monday, January 22, 2024

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

Key Points: 
  • USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
    COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.
  • The milestone relates to the validation of GMP manufacturing of finished product.
  • The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023.
  • Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

What if every germ hit you at the exact same time? An immunologist explains

Retrieved on: 
Tuesday, January 16, 2024

What would happen if all the diseases in the world hit us at the exact same time?

Key Points: 
  • What would happen if all the diseases in the world hit us at the exact same time?
  • – Gabriella, age 12, Irving, Texas
    What would happen if all the diseases in the world hit us at the exact same time?
  • – Gabriella, age 12, Irving, Texas When I was younger, I would watch “Batman” on my black-and-white television after school.
  • In fact, sometimes fighting off one enemy can leave a hole in your defenses that another opportunistic pathogen can take advantage of.

BAM! Understanding the rivals

  • The potential bad guys include cancer cells and dangerous microorganisms – including bacteria, viruses, fungi and more – that cause infections.
  • The immune system must also be careful not to damage healthy cells and beneficial microorganisms that live on and inside you.
  • Your skin, snot, saliva and tears form a critical first line of defense.
  • Gathering an army of immune cells to fight pathogens takes a lot of energy and makes you feel awful.

BOOM! Where are their weaknesses?

  • Pathogens have specific parts on their surfaces called pathogen associated molecular patterns, or PAMPs.
  • Because the same PAMP is present on many different pathogens, a strategy to combat one PAMP can defeat many pathogens.
  • There are molecules in cells all over your body that can recognize PAMPS and destroy anything those PAMPS are on.

SPLAT! Raising an army of defenders

  • When the virus that causes COVID-19 emerged in 2019, it was something people’s immune systems likely had never seen before.
  • The immune system makes many immune cells that are specific to antigens, or unique and recognizable parts of cancers and microorganisms, it hasn’t encountered before.
  • The DNA in each of these immune cells is different from the DNA in any other cell in your body.
  • Since pathogens can also multiply rapidly, clonal selection allows you to rapidly raise an army to fight them.
  • It would take a tremendous amount of energy and time to build an appropriate army against each microorganism all at once.


Joseph Larkin III receives funding from the Grayson Jockey Research Foundation, The National Institutes of Health, and industry.

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Retrieved on: 
Thursday, January 4, 2024

INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.

Key Points: 
  • INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.
  • “We are very pleased that the MAD part of the Phase I study exceeded the already compelling results from the SAD part of the study.
  • InflaRx currently plans to initiate a short-term dosing Phase II study towards the end of 2024, followed by a longer-term dosing Phase II study in 2025.
  • A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

Retrieved on: 
Friday, November 10, 2023

“There is a significant unmet medical need for the approximate 35,000 patients in the U.S. living with Stargardt disease,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen.

Key Points: 
  • “There is a significant unmet medical need for the approximate 35,000 patients in the U.S. living with Stargardt disease,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen.
  • OCU410ST utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene.
  • “It is important and exciting to pursue novel therapies for untreatable blinding diseases,” said Charles Wykoff, MD, PhD, Director of Research, Retina Consultants of Texas.
  • “Initiation of this trial program investigating a new mechanism of action for the treatment of Stargardt disease is inspiring and brings hope to patients and families.”

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of September 30, 2023 was $8.2 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended September 30, 2023 was $6.7 million or $0.08 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $4.3 million or $0.05 per basic share.

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Retrieved on: 
Thursday, November 9, 2023

WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized recent developments.
  • At the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, Monopar presented Phase 1b clinical trial results to-date.
  • Results for the Third Quarter Ended September 30, 2023 Compared to the Third Quarter Ended September 30, 2022
    Cash, cash equivalents and short-term investments as of September 30, 2023 were $8.5 million.
  • G&A expenses for the three months ended September 30, 2023 were $749,000, compared to $675,000 for the three months ended September 30, 2022.